6.00
+0.16(+2.74%)
Currency In USD
| Previous Close | 5.84 |
| Open | 5.93 |
| Day High | 6 |
| Day Low | 5.9 |
| 52-Week High | 18.43 |
| 52-Week Low | 3.1 |
| Volume | 43,749 |
| Average Volume | 674,568 |
| Market Cap | 38.24M |
| PE | -1.61 |
| EPS | -3.72 |
| Moving Average 50 Days | 4.83 |
| Moving Average 200 Days | 7.47 |
| Change | 0.16 |
If you invested $1000 in Exicure, Inc. (XCUR) since IPO date, it would be worth $12.9 as of December 24, 2025 at a share price of $6. Whereas If you bought $1000 worth of Exicure, Inc. (XCUR) shares 5 years ago, it would be worth $20.73 as of December 24, 2025 at a share price of $6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Dec 08, 2025 9:30 PM GMT
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluat
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025